Clinical trials: Active Population
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Inflammation, Crohn's Disease
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.
- Trial name
- NCT01203631
- Testing
- NNC 0142-0000-0002
- Where
- 23 sites in United States, Belgium and 6 more
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Tinea Versicolor
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor.
- Trial name
- NCT06305637
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Ocular Hypertension, Open Angle Glaucoma
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
- Trial name
- NCT01731002
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Aerie Pharmaceuticals
Essential Hypertension
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
- Trial name
- NCT07700875
- Testing
- QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 150 mg, QR01019 potassium salt 50 mg
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Surgical Hemorrhage
A Phase III Study of Hemofence for Hemostasis in Patients With Uncontrolled Exudative Hemorrhage During Spinal Or Orthopedic Surgery
This Phase 3 study was conducted to evaluated the efficacy and safety of Hemofence compared with Floseal Hemostatic Matrix in patients undergoing spinal or orthopedic surgery who required hemostasis for exudative bleeding that…
- Trial name
- NCT07824024
- Testing
- Hemofence, Floseal hemostatic matrix
- Where
- 3 sites in South Korea
- Volunteers
- 172 people
- Sponsor
- BMI Korea
Asthma
Efficacy and Safety of Different Doses of Indacaterol
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
- Trial name
- NCT01079130
- Testing
- Indacaterol, Salmeterol
- Where
- 71 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Influenza A, Influenza B, Influenza Vaccination
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older.
- Trial name
- GC3114B (NCT07883928)
- Testing
- vaccination of GC3114B, Vaccination of Efluelda
- Where
- South Korea
- Volunteers
- 1,806 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Hypertension
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure.
- Trial name
- NCT01870739
- Testing
- sacubitril/valsartan (LCZ696), olmesartan, Amlodipine (Optional)
- Where
- 4 sites in Germany, Switzerland and 1 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Stable Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to…
- Trial name
- NCT02949388
- Testing
- 400 mg (200 mg BID), 300 mg (150 mg BID)
- Where
- 34 sites in United States
- Volunteers
- 199 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Ulcerative Colitis
Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis
The purpose of this study is to investigate whether a novel dosage form of a prednisolone ester, called COLAL-PRED®, is useful in the treatment of ulcerative colitis.
- Trial name
- NCT00299013
- Testing
- COLAL-PRED®, Prednisolone
- Where
- 86 sites in Australia, Belgium and 13 more
- Volunteers
- 796 people
- Sponsor
- Alizyme
Diphtheria, Tetanus
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants
The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT04073459
- Testing
- DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118690
- Testing
- Fluticasone propionate/salmeterol
- Where
- 51 sites in United States
- Volunteers
- 227 people
- Sponsor
- GlaxoSmithKline
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- GOLD (NCT00329446)
- Testing
- Quetiapine Fumarate, Escitalopram oxylate
- Where
- 63 sites in United States
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Secondarily Infected Traumatic Skin Lesions
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
- Trial name
- NCT04155203
- Testing
- Mupirocin Calcium, Vehicle
- Where
- United States
- Volunteers
- 657 people
- Sponsor
- Padagis LLC
Type 2 Diabetes Mellitus
A Phase IV Study in Drug-Naive Patients With T2DM in China
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared with Acarbose in patients with T2DM who were…
- Trial name
- NCT03344341
- Testing
- Dapagliflozin, Acarbose
- Where
- 20 sites in China
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Neuropathic Pain
Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy
Epinosine B Forte ampoule is an intramuscular injectable supplement containing adenosine triphosphate (ATP), Cocarboxylase (vitamin B1 derivative), vitamin B12, and nicotinamide (vitamin B3).
- Trial name
- NCT07296354
- Testing
- adenosine triphosphate, Vitamin B Complex
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Egyptian International Pharmaceutical Industries Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.